T1	Participants 79 147	patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial.
T2	Participants 443 506	large cohort of patients presenting across the spectrum of ACS.
T3	Participants 537 548	(n = 3,761)
T4	Participants 583 658	patients randomized to atorvastatin 80 mg or pravastatin 40 mg after ACS in
T5	Participants 1006 1042	patients with elevated baseline PlGF
